Surgery plus niraparib for returning ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old
- Be well enough for treatment, with an ECOG of 0 to 2
- Have ovarian, fallopian tube, or primary peritoneal cancer that is “platinum-sensitive” and has returned (a second recurrence relapsed cancer)
- Have surgery planned for the first recurrence, and doctors believe all visible disease can be fully removed
- Limit of prior treatment: no more than two chemotherapy regimens before (maintenance treatments don’t count as extra chemo)
- You must not have had niraparib if you are in a “no prior PARP inhibitor” group (this trial has different cohorts)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
This trial tests a new treatment approach for people with ovarian cancer that has started to progress in a few spots (up to 3) after taking a PARP inhibitor. It combines targeted radiation (SBRT) to those spots, followed by another PARP inhibitor (niraparib), to see if this can control the cancer further.
This trial tests whether taking niraparib (a maintenance anti-cancer pill) for a shorter time after 3 cycles of platinum chemotherapy works as well as taking it after 6 cycles. It is for people with advanced ovarian cancer that has been fully removed (no visible tumor) and is “HRD-positive,” meaning it has certain DNA repair weaknesses.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
Hear when a new Fallopian Tube Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.